Tumor Biology

, Volume 34, Issue 3, pp 1553–1557 | Cite as

MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma

  • Da-Wei Chen
  • Yao-Fu Fan
  • Jiang Li
  • Xiao-Xiao Jiang
Research Article

Abstract

The aim of this study was to detect MTA2 expression in pancreatic ductal adenocarcinoma (PDA) and to analyze its association with prognosis of PDA patients. MTA2 mRNA and protein expression were determined by real-time quantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry in specimens of primary cancer and their adjacent noncancerous tissues in PDA patients. We found that MTA2 mRNA and protein expression levels were both significantly upregulated in PDA lesions compared with adjacent noncancerous tissues. Immunohistochemistry showed that high MTA2 expression was correlated with poor tumor differentiation, TNM stage, and lymph node metastasis. Kaplan–Meier survival analysis showed that patients with high expression levels of MTA2 showed lower overall survival rate than those with low expression levels. Multivariate analysis showed that high MTA2 protein expression was an independent prognostic factor for PDA patients. Our study suggests that overexpression of MTA2 may play an important role in the progression of PDA and MTA2 expression may serve as a biomarker for poor prognosis for PDA.

Keywords

MTA2 Prognosis Pancreatic ductal adenocarcinoma 

Notes

Conflicts of interest

None

References

  1. 1.
    Zimmon DS, Ferstenberg R. Pancreatic carcinoma. N Engl J Med. 1992;326:1782.PubMedCrossRefGoogle Scholar
  2. 2.
    Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Lin M, DiVito MM, Merajver SD, Boyanapalli M, van Golen KL. Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. Mol Cancer. 2005;4:21. doi: 10.1186/1476-4598-4-21.PubMedCrossRefGoogle Scholar
  4. 4.
    Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg. 2003;186:486–92. doi: 10.1016/j.amjsurg.2003.07.002.PubMedCrossRefGoogle Scholar
  5. 5.
    Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 2002;160:1745–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Toh Y, Kuninaka S, Endo K, Oshiro T, Ikeda Y, Nakashima H, et al. Molecular analysis of a candidate metastasis-associated gene, MTA1: possible interaction with histone deacetylase 1. J Exp Clin Cancer Res. 2000;19:105–11.PubMedGoogle Scholar
  7. 7.
    Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, et al. Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol. 2006;20:2020–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K, Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis. 2003;20:19–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem. 2002;277:35434–9. doi: 10.1074/jbc.M203455200.PubMedCrossRefGoogle Scholar
  10. 10.
    Wong JJ, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut. 2007;56:140–8. doi: 10.1136/gut.2005.088799.PubMedCrossRefGoogle Scholar
  11. 11.
    Yao YL, Yang WM. The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Biol Chem. 2003;278:42560–8. doi: 10.1074/jbc.M302955200.PubMedCrossRefGoogle Scholar
  12. 12.
    Sobin LH, Wittekind CH. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 199–202.Google Scholar
  13. 13.
    Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.PubMedGoogle Scholar
  14. 14.
    Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.PubMedCrossRefGoogle Scholar
  15. 15.
    Fujita N, Kajita M, Taysavang P, Wade PA. Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol Endocrinol. 2004;18:2937–49. doi: 10.1210/me.2004-0258.PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006;12:1479–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Adjei AA. Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002;29:50–3.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Da-Wei Chen
    • 1
  • Yao-Fu Fan
    • 2
  • Jiang Li
    • 3
  • Xiao-Xiao Jiang
    • 1
  1. 1.Department of GastroenterologyThe PLA 117 HospitalHangzhouChina
  2. 2.Department of Traditional Chinese MedicineFirst Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  3. 3.Department of Medical OncologyAffiliated Wuxi People’s Hospital of Nanjing Medical UniversityWuxiChina

Personalised recommendations